Celtaxsys -
Celtaxsys - Celtaxsys - Celtaxsys -
Celtaxsys -
Celtaxsys - Celtaxsys - Celtaxsys -
 

News


   

 

 

 

Celtaxsys Announces new President and Chief Executive Officer Greg Duncan

Atlanta, GA - The Celtaxsys Board of Directors today announced that Greg Duncan has been appointed as President and Chief Executive Officer (CEO) and will join the board of directors effective immediately.  Mr. Duncan joins Celtaxsys following his most recent role as an Executive Committee member and President of North America for Brussels based UCB, prior to which he served as a Senior Vice-President at Pfizer where his duties included leading US marketing, as well as President of their Latin America operations.  Greg will be based in Atlanta, Georgia.


Celtaxsys Announces Successful Completion of Phase 1 Clinical Trial for Development of CTX-4430

ATLANTA, GA – September 16, 2013 - Atlanta-based pharmaceutical discovery and development company, Celtaxsys, has successfully completed the first of two clinical trials in its Phase 1 program, and the first trial conducted through its Australia subsidiary, Celtaxsys Aus Pty Ltd.In this First-in-Human trial, CTX-4430 was administered orally to Healthy Volunteers in escalating doses (up to 200 mg/day for 2 weeks) and was well-tolerated at all doses. Results of the trial will be presented at the 27th Annual North American Cystic Fibrosis Conference in October.


Celtaxsys Restructures, Enhances Operational Focus.

ATLANTA, GA – September 9, 2013 - Celtaxsys, Inc., an Atlanta-based pharmaceutical discovery and development company, announced today that it has restructured its management and operations to focus on development of its lead clinical stage drug candidate, CTX-4430, for treatment of Cystic Fibrosis (CF) lung disease.


Mr. Khalil Barrage appointed to Celtaxsys Board of Directors.

SAN FRANCISCO, CA – June, 2013 — Celtaxsys Inc., a privately-held biopharmaceutical company developing a new class of drugs to treat chronic inflammatory disorders through innate immunity, today announced that Mr. Khalil Barrage has been appointed to the Board of Directors.


Celtaxsys Brings Leading Researchers in Respiratory Diseases Together to Serve on Medical Advisory Panel

SAN FRANCISCO, CA – January 23, 2013 — Celtaxsys, Inc., a privately-held biopharmaceutical company developing a new class of drugs to treat chronic inflammatory disorders through innate immunity, today announced the appointments of Edward E. Philpot, M.D, J. Stuart Elborn, M.D., Richard B. Moss, M.D., Steven M. Rowe, M.D., M.S.P.H., and Michael S. Schechter, M.D., M.P.H., to its new Medical Advisory Panel.


Celtaxsys Initiates Phase 1 Study of CTX-4430 Oral Treatment for Pulmonary Inflammation

SAN FRANCISCO, CA – January 3, 2013 - Celtaxsys, Inc., a private biopharmaceutical company developing a new class of drugs to treat chronic inflammatory disorders, today announced the initiation of a first-in-human Phase 1 clinical study of CTX-4430, which blocks the pro-inflammatory enzyme Leukotriene A4 Hydrolase (LTA4H).


Celtaxsys Acquires Clinical Stage Innate Immunity Drug for Inflammation

San Francisco, Calif., January 5, 2012 /PRNewswire / -- Celtaxsys, Inc. a privately held biotechnology company announced today that it has acquired CTX-4430 (formerly EP-501), a clinical stage drug candidate that inhibits the pro-inflammatory enzyme Leukotriene A4 Hydrolase (LTA4H), from Estrellita Pharmaceuticals, Inc.


Dr. H. Daniel Perez Joins Celtaxsys Board of Directors

SAN FRANCISCO, June 6, 2011 /PRNewswire/ -- Celtaxsys, Inc., a private biopharmaceutical company defining new therapeutics in inflammation, announces the appointment of life sciences industry veteran, H. Daniel Perez, M.D., to its Board of Directors (BOD).

 

       
Celtaxsys - Celtaxsys - Celtaxsys -
Celtaxsys - Celtaxsys -
Celtaxsys - Celtaxsys - Celtaxsys -
Copyright © 2014 Celtaxsys, Inc., Atlanta, GA

 

 

Drug Pipeline Home About Us Science Clinical Trials News Contact Us Celtaxsys